<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in people with unprovoked VTE - Robertson, L - 2021 | Cochrane Library</title> <meta content="Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in people with unprovoked VTE - Robertson, L - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010837.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in people with unprovoked VTE - Robertson, L - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010837.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010837.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in people with unprovoked VTE" name="citation_title"/> <meta content="Lindsay Robertson" name="citation_author"/> <meta content="University of York" name="citation_author_institution"/> <meta content="lindsay.robertson@york.ac.uk" name="citation_author_email"/> <meta content="Cathryn Broderick" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="Su Ern Yeoh" name="citation_author"/> <meta content="University of Glasgow" name="citation_author_institution"/> <meta content="Gerard Stansby" name="citation_author"/> <meta content="Freeman Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD010837.pub5" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/10/01" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010837.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010837.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010837.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Morbidity; *Neoplasms [complications]; Positron Emission Tomography Computed Tomography; Quality of Life; *Venous Thromboembolism [etiology]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010837.pub5&amp;doi=10.1002/14651858.CD010837.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="BqmVIxTs";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010837\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010837\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010837\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010837\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","fa","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010837.pub5",title:"Effect of testing for cancer on cancer\\u2010 or venous thromboembolism (VTE)\\u2010related mortality and morbidity in people with unprovoked VTE",firstPublishedDate:"Oct 1, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010837.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010837.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010837.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010837.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010837.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010837.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010837.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010837.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010837.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010837.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3254 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010837.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/full#CD010837-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/full#CD010837-sec-0062"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/full#CD010837-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/full#CD010837-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/full#CD010837-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/full#CD010837-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/full#CD010837-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/full#CD010837-sec-0054"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/appendices#CD010837-sec-0067"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/table_n/CD010837StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/table_n/CD010837StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in people with unprovoked VTE </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/information#CD010837-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Lindsay Robertson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/information#CD010837-cr-0005">Cathryn Broderick</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/information#CD010837-cr-0006">Su Ern Yeoh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010837.pub5/information#CD010837-cr-0007">Gerard Stansby</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/information/en#CD010837-sec-0074">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 01 October 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010837.pub5">https://doi.org/10.1002/14651858.CD010837.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010837-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010837-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010837-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010837-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010837-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010837-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010837-abs-0001" lang="en"> <section id="CD010837-sec-0001"> <h3 class="title" id="CD010837-sec-0001">Background</h3> <p>Venous thromboembolism (VTE) is a collective term for two conditions: deep vein thrombosis (DVT) and pulmonary embolism (PE). A proportion of people with VTE have no underlying or immediately predisposing risk factors and the VTE is referred to as unprovoked. Unprovoked VTE can often be the first clinical manifestation of an underlying malignancy. This has raised the question of whether people with an unprovoked VTE should be investigated for an underlying cancer. Treatment for VTE is different in cancer and non‐cancer patients and a correct diagnosis would ensure that people received the optimal treatment for VTE to prevent recurrence and further morbidity. Furthermore, an appropriate cancer diagnosis at an earlier stage could avoid the risk of cancer progression and lead to improvements in cancer‐related mortality and morbidity. This is the third update of the review first published in 2015. </p> </section> <section id="CD010837-sec-0002"> <h3 class="title" id="CD010837-sec-0002">Objectives</h3> <p>To determine whether testing for undiagnosed cancer in people with a first episode of unprovoked VTE (DVT of the lower limb or PE) is effective in reducing cancer‐ or VTE‐related mortality and morbidity and to determine which tests for cancer are best at identifying treatable cancers early. </p> </section> <section id="CD010837-sec-0003"> <h3 class="title" id="CD010837-sec-0003">Search methods</h3> <p>The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase and CINAHL databases and World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers to 5 May 2021. We also undertook reference checking to identify additional studies. </p> </section> <section id="CD010837-sec-0004"> <h3 class="title" id="CD010837-sec-0004">Selection criteria</h3> <p>Randomised and quasi‐randomised trials in which people with an unprovoked VTE were allocated to receive specific tests for identifying cancer or clinically indicated tests only were eligible for inclusion. </p> </section> <section id="CD010837-sec-0005"> <h3 class="title" id="CD010837-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected studies, assessed risk of bias and extracted data. We assessed the certainty of the evidence using GRADE criteria. We resolved any disagreements by discussion. The main outcomes of interest were all‐cause mortality, cancer‐related mortality and VTE‐related mortality. </p> </section> <section id="CD010837-sec-0006"> <h3 class="title" id="CD010837-sec-0006">Main results</h3> <p>No new studies were identified for this 2021 update. In total, four studies with 1644 participants are included. Two studies assessed the effect of extensive tests including computed tomography (CT) scanning versus tests at the physician's discretion, while the other two studies assessed the effect of standard testing plus positron emission tomography (PET)/CT scanning versus standard testing alone. For extensive tests including CT versus tests at the physician's discretion, the certainty of the evidence, as assessed according to GRADE, was low due to risk of bias (early termination of the studies). When comparing standard testing plus PET/CT scanning versus standard testing alone, the certainty of evidence was moderate due to a risk of detection bias. The certainty of the evidence was downgraded further as detection bias was present in one study with a low number of events. </p> <p>When comparing extensive tests including CT versus tests at the physician's discretion, pooled analysis on two studies showed that testing for cancer was consistent with either benefit or no benefit on cancer‐related mortality (odds ratio (OR) 0.49, 95% confidence interval (CI) 0.15 to 1.67; 396 participants; 2 studies; low‐certainty evidence). One study (201 participants) showed that, overall, malignancies were less advanced at diagnosis in extensively tested participants than in participants in the control group. In total, 9/13 participants diagnosed with cancer in the extensively tested group had a T1 or T2 stage malignancy compared to 2/10 participants diagnosed with cancer in the control group (OR 5.00, 95% CI 1.05 to 23.76; low‐certainty evidence). There was no clear difference in detection of advanced stages between extensive tests versus tests at the physician's discretion: one participant in the extensively tested group had stage T3 compared with four participants in the control group (OR 0.25, 95% CI 0.03 to 2.28; low‐certainty evidence). In addition, extensively tested participants were diagnosed earlier than control group (mean: 1 month with extensive tests versus 11.6 months with tests at physician's discretion to cancer diagnosis from the time of diagnosis of VTE). Extensive testing did not increase the frequency of an underlying cancer diagnosis (OR 1.32, 95% CI 0.59 to 2.93; 396 participants; 2 studies; low‐certainty evidence). Neither study measured all‐cause mortality, VTE‐related morbidity and mortality, complications of anticoagulation, adverse effects of cancer tests, participant satisfaction or quality of life. </p> <p>When comparing standard testing plus PET/CT screening versus standard testing alone, standard testing plus PET/CT screening was consistent with either benefit or no benefit on all‐cause mortality (OR 1.22, 95% CI 0.49 to 3.04; 1248 participants; 2 studies; moderate‐certainty evidence), cancer‐related mortality (OR 0.55, 95% CI 0.20 to 1.52; 1248 participants; 2 studies; moderate‐certainty evidence) or VTE‐related morbidity (OR 1.02, 95% CI 0.48 to 2.17; 854 participants; 1 study; moderate‐certainty evidence). Regarding stage of cancer, there was no clear difference for detection of early (OR 1.78, 95% 0.51 to 6.17; 394 participants; 1 study; low‐certainty evidence) or advanced (OR 1.00, 95% CI 0.14 to 7.17; 394 participants; 1 study; low‐certainty evidence) stages of cancer. There was also no clear difference in the frequency of an underlying cancer diagnosis (OR 1.71, 95% CI 0.91 to 3.20; 1248 participants; 2 studies; moderate‐certainty evidence). Time to cancer diagnosis was 4.2 months in the standard testing group and 4.0 months in the standard testing plus PET/CT group (P = 0.88). Neither study measured VTE‐related mortality, complications of anticoagulation, adverse effects of cancer tests, participant satisfaction or quality of life. </p> </section> <section id="CD010837-sec-0007"> <h3 class="title" id="CD010837-sec-0007">Authors' conclusions</h3> <p>Specific testing for cancer in people with unprovoked VTE may lead to earlier diagnosis of cancer at an earlier stage of the disease. However, there is currently insufficient evidence to draw definitive conclusions concerning the effectiveness of testing for undiagnosed cancer in people with a first episode of unprovoked VTE (DVT or PE) in reducing cancer‐ or VTE‐related morbidity and mortality. The results could be consistent with either benefit or no benefit. Further good‐quality large‐scale randomised controlled trials are required before firm conclusions can be made. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010837-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010837-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010837-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010837-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010837-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010837-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010837-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010837-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010837-abs-0002" lang="en"> <h3>Does testing for cancer in people with unprovoked blood clots in the legs and lungs reduce cancer‐ and blood clot‐related death and illness? </h3> <p><b>Key message</b> </p> <p>This review found that there are too few trials to determine whether testing for undiagnosed cancer in people with a first unprovoked venous thromboembolism (VTE) is effective in reducing cancer‐ and VTE‐related deaths and illness. Further good‐quality and large‐scale studies are required. </p> <p><b>Why is this question important?</b> </p> <p>Venous thromboembolism (VTE) refers to blood clots in leg veins (known as deep venous thrombosis (DVT)), which can travel to the lungs (causing pulmonary embolism (PE)). PE can often be fatal. Signs of DVT include pain and swelling of the leg while signs of PE include breathlessness and chest pain. Risk factors for VTE include surgery, prolonged bed rest, trauma, family history, pregnancy, and blood deficiencies. Sometimes a VTE happens for no apparent reason (it is unprovoked). In such people, undetected cancer may be the cause of the VTE. This has raised the question of whether people with an unprovoked VTE should be investigated for underlying cancer. This is important as the management of VTE in people with and without cancer differs. A cancer diagnosis would ensure people receive the optimal treatment to reduce the risk of another VTE. A diagnosis could also lead to the cancer being treated earlier, at a more curable stage. </p> <p><b>What did we do?</b> </p> <p>We searched for randomised controlled studies that assessed whether testing for undiagnosed cancer in people with a first unprovoked VTE (DVT or PE) was effective in reducing cancer and VTE‐related illness and death. In randomised controlled studies the treatments or tests people receive are decided at random and these usually give the most reliable evidence about treatment effects. </p> <p><b>What did we find?</b> </p> <p>We found four studies with 1644 participants. Two studies compared extensive cancer tests with tests carried out at the physician's discretion and two studies compared cancer tests plus scanning with cancer tests alone. Combining the results of the two studies showed that extensive testing had no effect on the number of cancer‐related deaths. Additionally, extensive testing did not identify more people with cancer. However, extensive testing did identify cancers at an earlier stage (approximately 10 months earlier) and cancers were less advanced in people in the extensive testing group than in people in the group with tests carried out at the physician's discretion. Neither study looked at the number of deaths due to any cause, deaths and illness associated with VTE, side effects of cancer tests, side effects of VTE treatment or participant satisfaction. Two studies that compared tests plus scanning with tests alone showed that adding computed tomography scanning had little or no effect on the number of deaths, cancer‐related deaths, illness associated with VTE; nor did it identify more people with cancer, or show a clear difference in time to diagnosis or stages of cancer diagnosed. Neither study looked at deaths associated with VTE, side effects of cancer tests, side effects of VTE treatment, participant satisfaction or quality of life. </p> <p><b>How certain are we in the evidence?</b> </p> <p>When comparing extensive tests versus tests at the physician's discretion, the certainty of the evidence was low due to bias caused by two of the studies stopping early. When comparing tests plus PET/CT scanning with tests alone, the certainty of the evidence ranged from low to moderate due to issues with how the studies were designed, imprecision caused by a low number of events and bias due to lack of blinding of people assessing the effects. </p> <p><b>How up to date is this evidence?</b> </p> <p>This Cochrane review updates our previous evidence. The evidence is current to May 2021. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010837-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010837-sec-0062"></div> <h3 class="title" id="CD010837-sec-0063">Implications for practice</h3> <section id="CD010837-sec-0063"> <p>At present, there is insufficient evidence as to whether testing for undiagnosed cancer in people with a first episode of unprovoked venous thromboembolism (VTE) (deep vein thrombosis (DVT) of the lower limb or pulmonary embolism (PE)) is effective in reducing cancer‐ and VTE‐related mortality and morbidity, and which tests for cancer are best at identifying treatable cancers early. The decision whether to screen for cancer or not in a first episode of unprovoked VTE remains for individual clinicians and participants to decide on a case‐by‐case basis. The diagnosis of cancer has significant implications for participants and may alter the pharmacological treatment of their VTE, and some may wish to be investigated even in the absence of a survival benefit. </p> </section> <h3 class="title" id="CD010837-sec-0064">Implications for research</h3> <section id="CD010837-sec-0064"> <p>The low number of studies in this systematic review confirms the need for further methodologically sound and large randomised controlled trials. They should be adequately powered to look at key endpoints including mortality, as well as addressing questions concerning the types of test to be used, quality of life and participant preference. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010837-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010837-sec-0008"></div> <div class="table" id="CD010837-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Extensive tests versus tests at the physician's discretion</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Extensive tests versus tests at the physician's discretion</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with unprovoked VTE </p> <p><b>Setting:</b> hospital </p> <p><b>Intervention:</b> extensive tests </p> <p><b>Comparison:</b> tests at the physician's discretion </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with tests at physician's discretion</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with extensive tests</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cancer‐related mortality</b><sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.49<br/>(0.15 to 1.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>396<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>(6 to 65) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VTE‐related mortality</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VTE‐related morbidity</b><sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stage of cancer ‐ early</b><sup>6</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 5.00<br/>(1.05 to 23.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>201</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000<br/>(21 to 322) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stage of cancer ‐ advanced</b><sup>8</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.25<br/>(0.03 to 2.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>201<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/>(1 to 85) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to cancer diagnosis</b><sup>9</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to cancer diagnosis (measured from time of diagnosis of VTE) measured in 1 study (<a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a>), and reported as a mean of 1 month with extensive tests compared to 11.6 months with tests at physician's discretion (P &lt; 0.001). Standard deviations for these means not given. Attempts to contact author for these data made but no response received. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency of underlying cancer diagnosis</b><sup>10</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 1000<br/>(36 to 158) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.32<br/>(0.59 to 2.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>396<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Death due to any cause.<br/><sup>2</sup> Defined as death due to malignant disease itself, or death due to complications of treatments or procedures to diagnose or treat cancer.<br/><sup>3</sup> Risk of bias was high in two included studies (<a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a>; <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a>). <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a> terminated early after inclusion of only 201 participants after 5 years for several reasons. First, only five of more than 40 potential participating centres could contribute participants to study. Second, some medical ethics committees rejected the protocol because of absence of screening for occult cancer in the control group, other centres could not start because the proposed extensive screening was judged unethical. Finally, identification of cancer at an apparent early stage in extensive screening group led to an increasing tendency among physicians in participating hospitals to initiate screening for cancer in control participants. <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a> study terminated early due to low recruitment rate and failure to show an appreciable advantage of CT‐based strategy over control strategy for detection of cancer.<br/><sup>4</sup> Fatal pulmonary embolism (PE). PE diagnosed "on the basis of a lung scan indicating a high probability of its presence, as indicated by the presence of new or enlarged areas of segmental perfusion defects with ventilation‐perfusion mismatch; an abnormal perfusion scan with documentation of new or recurrent deep vein thrombosis (DVT); the presence of non‐enhancing filling defects in the central pulmonary vasculature on helical computed tomography; a finding of intraluminal filling defects on pulmonary angiography; or evidence of fresh PE at autopsy" (<a href="./references#CD010837-bbs2-0024" title="LeeAYY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53.">Lee 2003b</a>). Fatal PE including probable fatal PE and unexplained sudden death used if reported, as defined by individual studies.<br/><sup>5</sup> Frequency of recurrent VTE. Recurrent PE or DVT diagnosed if a previously compressible proximal venous segment or segments could no longer be compressed on ultrasonography or if there were constant intraluminal filling defects in two or more projections on venography. Unequivocal extension of the thrombus required for diagnosis of recurrence if results abnormal on previous testing (<a href="./references#CD010837-bbs2-0024" title="LeeAYY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53.">Lee 2003b</a>)<br/><sup>6</sup> Early‐stage malignancies, defined as T1 or T2 without locoregional or distant metastases (N0 M0).<br/><sup>7</sup> Certainty of evidence downgraded for imprecision due to low number of events. Evidence downgraded further as risk of bias high in <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a>. Study terminated early after inclusion of only 201 participants after five years for several reasons. First, only five of more than 40 potential participating centres could contribute participants to study. Second, some medical ethics committees rejected the protocol because of absence of screening for occult cancer in the control group, other centres could not start because the proposed extensive screening was judged unethical. Finally, identification of cancer at an apparent early stage in extensive screening group led to an increasing tendency among physicians in participating hospitals to initiate screening for cancer in control participants.<br/><sup>8</sup> Advanced‐stage malignancies, defined as T3 with locoregional or distant metastases (N1 or M1).<br/><sup>9</sup> Time to cancer diagnosis, as defined in included studies.<br/><sup>10</sup> Frequency of an underlying cancer diagnosis (i.e. number of times cancer diagnosed through screening following an unprovoked VTE as defined in included studies) at time of VTE presentation and overall over follow‐up period. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010837-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Standard testing plus PET/CT scanning versus standard testing alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Standard testing plus PET/CT scanning versus standard testing alone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with unprovoked VTE </p> <p><b>Setting:</b> hospital </p> <p><b>Intervention:</b> standard testing + PET/CT scanning </p> <p><b>Comparison:</b> standard testing alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with standard testing alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with standard testing + PET/CT scanning</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.22<br/>(0.49 to 3.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1248<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000<br/>(7 to 42) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cancer‐related mortality</b><sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.55<br/>(0.20 to 1.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1248<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/>(4 to 26) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VTE‐related mortality</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>VTE‐related morbidity</b><sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.02<br/>(0.48 to 2.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>854<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000<br/>(16 to 68) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stage of cancer ‐ early</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.78<br/>(0.51 to 6.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>394<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2,6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/>(10 to 113) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stage of cancer ‐ advanced</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.00<br/>(0.14 to 7.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>394<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2,6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/>(1 to 69) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to cancer diagnosis</b><sup>7</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>854</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to cancer diagnosis measured in <a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a> as 4.2 months in standard testing group and 4.0 months in standard testing + PET/CT group (P = 0.88). However, standard deviations for these means not given. Attempts made to contact author for these data but no response received. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Frequency of an underlying cancer diagnosis</b><sup>8</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.71<br/>(0.91 to 3.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1248<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000<br/>(26 to 86) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>PET/CT:</b> positron emission tomography/computed tomography; <b>RCT:</b> randomised controlled trial; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Death due to any cause.<br/><sup>2</sup> Certainty of evidence downgraded as risk of detection bias high for one study as outcome assessors not blinded to treatment (<a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a>).<br/><sup>3</sup> Defined as death due to malignant disease itself, or death due to complications of treatments or procedures to diagnose or treat cancer.<br/><sup>4</sup> Fatal pulmonary embolism (PE). PE diagnosed "on the basis of a lung scan indicating a high probability of its presence, as indicated by the presence of new or enlarged areas of segmental perfusion defects with ventilation‐perfusion mismatch; an abnormal perfusion scan with documentation of new or recurrent deep vein thrombosis (DVT); the presence of non‐enhancing filling defects in the central pulmonary vasculature on helical computed tomography; a finding of intraluminal filling defects on pulmonary angiography; or evidence of fresh PE at autopsy" (<a href="./references#CD010837-bbs2-0024" title="LeeAYY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53.">Lee 2003b</a>). Fatal PE including probable fatal PE and unexplained sudden death used if reported, as defined by individual studies.<br/><sup>5</sup> Frequency of recurrent VTE. Recurrent PE or DVT diagnosed if a previously compressible proximal venous segment or segments could no longer be compressed on ultrasonography or if there were constant intraluminal filling defects in two or more projections on venography.<br/><sup>6</sup> Certainty of evidence downgraded for imprecision due to low number of events.<br/><sup>7</sup> Time to cancer diagnosis, as defined in included studies.<br/><sup>8</sup> Frequency of an underlying cancer diagnosis (i.e. number of times cancer diagnosed through screening following an unprovoked VTE as defined in included studies) at time of VTE presentation and overall over follow‐up period. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010837-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010837-sec-0009"></div> <section id="CD010837-sec-0010"> <h3 class="title" id="CD010837-sec-0010">Description of the condition</h3> <p>Venous thromboembolism (VTE) is the collective term for the clinical conditions deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT is the formation of a blood clot (thrombus) in a deep vein, predominantly in the legs. Symptoms include pain, tenderness, erythema and swelling of the affected leg. PE occurs when part or all the thrombus breaks off (embolises) and travels up to the lungs blocking the pulmonary arteries. Symptoms of PE include breathlessness and chest pain (<a href="./references#CD010837-bbs2-0011" title="BlannAD , LipGY . Venous thromboembolism. BMJ2006;332(7535):215-9.">Blann 2006</a>). </p> <p>Guidelines published by the UK National Institute for Health and Care Excellence (NICE) recommend that people with a suspected VTE should be risk stratified using various diagnostic investigations. Anticoagulant therapy with low molecular weight heparin (LMWH) should be administered in the interim. People with confirmed VTE should receive LMWH or fondaparinux for at least the initial five days and be started on a vitamin K antagonist. The LMWH should be stopped when the international normalised ratio has been above 2 for at least 24 hours. Vitamin K antagonists should be continued for at least three months. In people with an unprovoked VTE, consideration should be given to extending anticoagulation beyond three months. However, people with cancer‐associated VTE should be treated with LMWH from the initial diagnosis for a period of six months, and considered for continuation of anticoagulation with either LMWH or a vitamin K antagonist based on the status of the underlying cancer and risks of anticoagulation (<a href="./references#CD010837-bbs2-0031" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. NICE Guideline 158. www.nice.org.uk/guidance/ng158 (accessed 16 September 2021).">NICE 2020</a>). Direct oral anticoagulants (DOACs) such as rivaroxaban have been used for the initial treatment and prevention of recurrent VTE. Two systematic reviews have shown that DOACs may be as safe and effective as conventional anticoagulation for the prevention of recurrent VTE in people with cancer but, direct comparisons to the current standard of care with LMWH are limited (<a href="./references#CD010837-bbs2-0013" title="CarrierM , CameronC , DellucA , CastellucciL , KhoranaAA , LeeAY . Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thrombosis Research2014;134(6):1214-9.">Carrier 2014</a>; <a href="./references#CD010837-bbs2-0044" title="VedovatiMC , GerminiF , AgnelliG , BecattiniC . Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest2015;147(2):475-83.">Vedovati 2015</a>). </p> <p>The difference in management of people with a cancer‐associated VTE is due to their significantly higher risk of VTE recurrence, which is estimated to be three times higher than in people with VTE in the absence of cancer (<a href="./references#CD010837-bbs2-0026" title="LevitanN , DowlatiA , RemickSC , TahsildarHI , SivinskiLD , BeythR , et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore)1999;78(5):285-91.">Levitan 1999</a>). Furthermore, people with cancer and an associated VTE have a poorer overall prognosis compared to people without a VTE (<a href="./references#CD010837-bbs2-0040" title="SorensenHT , MellemkjaerL , OlsenJH , BaronJA . Prognosis of cancers associated with venous thromboembolism. New England Journal of Medicine2000;343:1846-50.">Sorensen 2000</a>). </p> <p>A proportion of people with VTE have no underlying or immediately apparent cause and the VTE is referred to as unprovoked. Unprovoked VTE can suggest underlying malignancies such as cancer of the blood, kidney, ovary, pancreas, stomach and lung (<a href="./references#CD010837-bbs2-0010" title="BickRL . Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Seminars in Thrombosis and Hemostasis1978;5(1):1-26.">Bick 1978</a>; <a href="./references#CD010837-bbs2-0021" title="KakkarAK , LevineM , PinedoHM , WolffR , WongJ . Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist2003;8(4):381-8.">Kakkar 2003</a>; <a href="./references#CD010837-bbs2-0023" title="LeeAY , LevineMN . Venous thromboembolism and cancer: risks and outcomes. Circulation2003;107(23 Suppl 1):I17-21.">Lee 2003a</a>; <a href="./references#CD010837-bbs2-0033" title="PrandoniP , PiccioliA . Venous thromboembolism and cancer: a two-way clinical association. Frontiers in Bioscience1997;2:e12-21.">Prandoni 1997</a>; <a href="./references#CD010837-bbs2-0045" title="WhiteRH , ChewHK , ZhouH , Parikh-PatelA , HarrisD , HarveyD , et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Archives of Internal Medicine2005;165(15):1782-7.">White 2005</a>). Results from one Swedish prospective cohort study of almost 62,000 participants determined that the standardised incidence ratio of a cancer diagnosis within the first two years of an unprovoked VTE was 4.4 (<a href="./references#CD010837-bbs2-0009" title="BaronJA , GridleyG , WeiderpassE , NyrenO , LinetM . Venous thromboembolism and cancer. Lancet1998;351(9109):1077-80.">Baron 1998</a>), and there was an overall absolute incidence of cancer of 11% (<a href="./references#CD010837-bbs2-0030" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. NICE Clinical Guideline 144. www.nice.org.uk/guidance/cg144 (accessed 2 August 2017).">NICE 2012</a>). One study of 339 participants with a first episode of an unprovoked VTE determined that the risk ratio (RR) of cancer‐related mortality at two years was 0.52 (95% confidence interval (CI) 0.10 to 2.75) in people undergoing intensive investigations compared to routine tests, while the RR for early‐stage cancer detection was 3.21 (95% CI 0.88 to 11.79) (<a href="./references#CD010837-bbs2-0032" title="PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al, SOMIT Investigators Group. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2(6):884-9.">Piccioli 2004a</a>). </p> <p>Therefore, people who present with an apparent unprovoked VTE have a significant underlying risk of malignancy or cancer‐associated VTE, with significant implications for the management of the VTE itself (three months' vitamin K antagonist versus six months' LMWH), the prognosis related to risk of VTE recurrence and the precipitating cancer. NICE guidelines recommend that all people presenting with a first episode of unprovoked VTE (DVT or PE) should undergo a medical history review and baseline blood test results including full blood count, renal and hepatic function, PT and APTT, and offer a physical examination (<a href="./references#CD010837-bbs2-0031" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. NICE Guideline 158. www.nice.org.uk/guidance/ng158 (accessed 16 September 2021).">NICE 2020</a>). This is consistent with other guidelines (<a href="./references#CD010837-bbs2-0020" title="DellucA , AnticD , LecumberriR , AyC , MeyerG , CarrierM . Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH. Journal of Thrombsis and Haemostasis2017;15(10):2076-9.">ISTH 2017</a>). If these initial investigations suggest signs and symptoms of cancer then further tests including abdomino‐pelvic computed tomography (CT) and positron emission tomography (PET) scans and ultrasound, are recommended. For people presenting with VTE at unusual sites (e.g. splanchnic vein thrombosis), further imaging tests are not recommended because the CT scans used for the initial diagnosis would be adequate for occult cancer detection. Given the higher prevalence of JAK2 mutation in patients with splanchnic vein thrombosis, JAK2V617F mutation testing to screen for a myeloproliferative disorder should be considered in patients with unprovoked events (<a href="./references#CD010837-bbs2-0020" title="DellucA , AnticD , LecumberriR , AyC , MeyerG , CarrierM . Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH. Journal of Thrombsis and Haemostasis2017;15(10):2076-9.">ISTH 2017</a>). </p> <p>Detection of cancer at an earlier stage enables more effective treatment. This has raised the question of whether people with an unprovoked VTE should be investigated for underlying cancer. Some authors have referred to this as 'screening for cancer' although this is somewhat misleading as screening refers to the investigation of asymptomatic people. Instead, people with VTE are better regarded as presenting with symptoms suggestive of underlying cancer and the aim of investigations is to refine the diagnosis of VTE based on the underlying cause, so that the person may receive a more accurate diagnosis and appropriate treatment for their VTE. In this context, VTE represents a symptom rather than a diagnosis per se. So, to what extent should people with an unprovoked VTE be investigated for a potential underlying cancer? It is the value of these additional tests which is the subject of this review. </p> </section> <section id="CD010837-sec-0011"> <h3 class="title" id="CD010837-sec-0011">Description of the intervention</h3> <p>A number of imaging techniques are used in the detection of cancers including computed tomography (CT), positron emission tomography (PET) and ultrasound (US). </p> <p>CT scans use x‐rays to produce cross‐sectional, three‐dimensional, images of structural changes due to malignancy. An intravenous, iodine agent is used to increase the contrast between the tumour and normal tissue. CT provides a very high spatial resolution but is limited in its ability to accurately distinguish between benign and malignant tissue on the basis of structural information alone, and image interpretation can be difficult where normal anatomy is distorted (<a href="./references#CD010837-bbs2-0015" title="ChinBB . Clinical utility of combined 18F-fluor-2-deoxyglucose positron emission tomography-computed tomography in the evaluation of gastrointestinal malignancies. Current Medical Imaging Reviews2008;4(4):255-69.">Chin 2008</a>). </p> <p>A PET scan uses low‐dose radiation to measure the activity of cells, producing images that represent the functional rather than anatomical characteristics of disease. 18F‐fluoro‐2‐deoxy‐D‐glucose (FDG) is used as a contrast agent as it is taken up strongly by many aggressive malignant tumours, but weakly by any normal physiological structures of the human body, resulting in an excellent lesion‐to‐background contrast (<a href="./references#CD010837-bbs2-0012" title="ButhiauD , RixeO , SpanoJP , NizriD , DelgadoM , GutierrezM , et al. New imaging techniques in oncology. European Journal of Cancer Supplements2003;1(2):28-42.">Buthiau 2003</a>). FDG‐PET imaging alone is limited by a lack of anatomical data so it is combined with CT in a single machine that performs both imaging techniques. Integrated PET/CT images combining the anatomical data of CT with the functional data of PET imaging, can detect lesions smaller than 1 cm which other imaging techniques cannot clearly classify as benign or malignant (<a href="./references#CD010837-bbs2-0012" title="ButhiauD , RixeO , SpanoJP , NizriD , DelgadoM , GutierrezM , et al. New imaging techniques in oncology. European Journal of Cancer Supplements2003;1(2):28-42.">Buthiau 2003</a>; <a href="./references#CD010837-bbs2-0014" title="ChenYK , DingHJ , SuCT , ShenYY , ChenLK , LiaoAC , et al. Application of PET and PET/CT imaging for cancer screening. Anticancer Research2004;24(6):4103-8.">Chen 2004</a>; <a href="./references#CD010837-bbs2-0039" title="SchöderH , GönenM . Screening for cancer with PET and PET/CT: potential and limitations. Journal of Nuclear Medicine2007;48(1):4S–18S.">Schöder 2007</a>). </p> <p>Ultrasound scanning uses high frequency sound waves to build up a picture of internal organs. The sound waves echo differently when bounced off healthy and abnormal tissue. While US can distinguish fluid‐filled cysts from solid tumours, it cannot tell if a tumour is malignant. The images are not as detailed as CT or MRI scan images and it is limited to specific parts of the body as the waves cannot travel through air (the lungs) or bone. US is one of the most common imaging methods used in the diagnosis of tumours in the thyroid, breast, prostate, liver, pancreatic, ovarian, uterine and kidney (<a href="./references#CD010837-bbs2-0018" title="FassL . Imaging and cancer: a review. Molecular Oncology2008;2(2):115-52.">Fass 2008</a>). </p> </section> <section id="CD010837-sec-0012"> <h3 class="title" id="CD010837-sec-0012">How the intervention might work</h3> <p>The interventions for detecting an underlying cancer will enable a diagnosis of cancer‐associated VTE to be made. This will enable the person to receive appropriate anticoagulation with LMWH versus vitamin K antagonist, for six versus three months respectively, and for the underlying cancer to be treated promptly without the need for additional symptoms to emerge before it is diagnosed. One study has shown that the combination of tests recommended by NICE detects cancer in approximately 10% of people with a first episode of unprovoked VTE and with no prior cancer diagnosis (<a href="./references#CD010837-bbs2-0032" title="PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al, SOMIT Investigators Group. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2(6):884-9.">Piccioli 2004a</a>). However, tests for cancer also have the potential for harm, from the pain and inconvenience of blood tests to more serious complications due to radiation exposure from X‐rays and CT scans. </p> </section> <section id="CD010837-sec-0013"> <h3 class="title" id="CD010837-sec-0013">Why it is important to do this review</h3> <p>The pharmacological management of VTE in people with and without cancer is considerably different, both in terms of choice of agent and duration of anticoagulation. Therefore, an appropriate cancer diagnosis would ensure that people received the optimal form and duration of anticoagulation, which, in turn, could reduce the overall population VTE recurrence rate and associated morbidity. Establishing whether a person with an apparently unprovoked VTE has an underlying cancer is important since this may lead to cancer diagnosis at an earlier, potentially curative stage, avoiding the risk of cancer progression while waiting for additional symptoms. This may, in turn, lead to improvements in cancer‐related mortality and morbidity. To date, no systematic review has been conducted to measure the effectiveness of testing for cancer in people with an unprovoked VTE. This review provides evidence as to whether such tests for underlying cancer, followed by appropriate alteration in the management or treatment of VTE, or both, are effective in reducing morbidity (VTE recurrence) and mortality (VTE‐ and cancer‐associated). This is the third update of the review first published in 2015. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010837-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010837-sec-0014"></div> <p>To determine whether testing for undiagnosed cancer in people with a first episode of unprovoked VTE (DVT of the lower limb or PE) is effective in reducing cancer‐ and VTE‐related mortality and morbidity and to determine which tests for cancer are best at identifying treatable cancers early. </p> <p>The detailed objectives are as follows:</p> <p> <ul id="CD010837-list-0001"> <li> <p>to determine whether testing for undiagnosed cancer in people with a first episode of unprovoked VTE (DVT of the lower limb or PE) is effective in reducing cancer mortality and morbidity (cancer morbidity being the need for cancer treatment and effects producing reduced quality of life); </p> </li> <li> <p>to determine whether testing for undiagnosed cancer in people with a first episode of unprovoked VTE (DVT or PE) is effective in reducing VTE‐related mortality and morbidity; </p> </li> <li> <p>to determine which tests for cancer are best at identifying treatable cancers early.</p> </li> </ul> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010837-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010837-sec-0015"></div> <section id="CD010837-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010837-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised and quasi‐randomised trials (where a method of allocation was used that was not truly random) in which people with an unprovoked VTE were allocated to receive different tests for cancer or tests as per physician discretion. We looked primarily at randomisation within three months of a VTE, as used in the SOMIT trial (<a href="./references#CD010837-bbs2-0032" title="PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al, SOMIT Investigators Group. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2(6):884-9.">Piccioli 2004a</a>). However, we also included trials where randomisation occurred at different time points as a subgroup analysis. We included published studies and studies in progress if preliminary results were available. Non‐English language studies were also eligible for inclusion in the review. </p> </section> <section id="CD010837-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included people with a first episode of unprovoked VTE (DVT of the lower limb or PE) with no pre‐existing or clinically apparent cancer diagnosis. </p> </section> <section id="CD010837-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included tests for cancer (e.g. complete blood count, serum calcium, liver function test, urinalysis, chest X‐ray, all forms of CT imaging, mammogram, tumour markers, sputum cytology, ultrasonography, positron emission tomography (PET) scan and colonoscopy) versus no tests for cancer or alternative tests, followed by appropriate treatment for cancer or change in VTE treatment regimen, or both. We excluded studies where these tests were routinely used in all groups. We included any study that focused on some other aspect of care than cancer only if the test for cancer was the subject of randomisation. </p> </section> <section id="CD010837-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD010837-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010837-list-0002"> <li> <p>All‐cause mortality (death due to any cause).</p> </li> <li> <p>Cancer‐related mortality (defined as death due to a malignant disease itself, or death due to complications of treatments or procedures to diagnose or treat the cancer). </p> </li> <li> <p>VTE‐related mortality (fatal PE). PE diagnosed "on the basis of a lung scan indicating a high probability of its presence, as indicated by the presence of new or enlarged areas of segmental perfusion defects with ventilation‐perfusion mismatch; an abnormal perfusion scan with documentation of new or recurrent DVT; the presence of non‐enhancing filling defects in the central pulmonary vasculature on helical CT; a finding of intraluminal filling defects on pulmonary angiography; or evidence of fresh PE at autopsy" (<a href="./references#CD010837-bbs2-0024" title="LeeAYY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53.">Lee 2003b</a>). Fatal PE including probable fatal PE and unexplained sudden death were used if reported, as defined by individual studies. </p> </li> </ul> </p> </section> <section id="CD010837-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010837-list-0003"> <li> <p>VTE‐related morbidity (e.g. frequency of recurrent VTE). Recurrent PE or DVT was diagnosed if a previously compressible proximal venous segment or segments could no longer be compressed on ultrasonography or if there were constant intraluminal filling defects in two or more projections on venography. Unequivocal extension of the thrombus required for the diagnosis of recurrence if the results were abnormal on previous testing (<a href="./references#CD010837-bbs2-0024" title="LeeAYY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53.">Lee 2003b</a>). </p> </li> <li> <p>Complications of anticoagulation (e.g. warfarin‐ versus LMWH‐associated bleeding). We reported on major bleeding and minor bleeding if reported in the included studies. Major bleeding included bleeding associated with death, bleeding at a critical site (intracranial, intraspinal, intraocular, retroperitoneal or pericardial area), bleeding resulting in a need for a transfusion of at least two units of blood or bleeding leading to a drop in haemoglobin of at least 2.0 g/dL (<a href="./references#CD010837-bbs2-0024" title="LeeAYY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53.">Lee 2003b</a>). Minor bleeding included any other bleeding. </p> </li> <li> <p>Adverse effects of cancer tests (e.g. radiation exposure, bleeding, as defined in included studies). </p> </li> <li> <p>Characteristics of diagnosed cancer (e.g. primary tumour, stage, localised (curable) versus advanced (palliative) as defined in included studies). </p> </li> <li> <p>Time to cancer diagnosis, as defined in included studies.</p> </li> <li> <p>Frequency of an underlying cancer diagnosis (i.e. the number of times cancer was diagnosed through screening following an unprovoked VTE as defined in included studies) at the time of VTE presentation and overall over the follow‐up period. </p> </li> <li> <p>Participant satisfaction (if assessed in individual studies, we reported results descriptively using the definition provided by the trialists). </p> </li> <li> <p>Quality of life.</p> </li> </ul> </p> </section> </section> </section> <section id="CD010837-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>There were no restrictions on date or language of publication.</p> <section id="CD010837-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Vascular Information Specialist conducted systematic searches of the following databases for randomised controlled trials and quasi‐randomised trials. </p> <p> <ul id="CD010837-list-0004"> <li> <p>The Cochrane Vascular Specialised Register via the Cochrane Register of Studies (CRS‐Web searched on 5 May 2021). </p> </li> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) Cochrane Register of Studies Online (CRSO 2021, Issue 4). </p> </li> <li> <p>MEDLINE (Ovid MEDLINE Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE) (searched from 11 July 2018 to 5 May 2021). </p> </li> <li> <p>Embase Ovid (searched from 11 July 2018 to 5 May 2021).</p> </li> <li> <p>CINAHL Ebsco (searched from 11 July 2018 to 5 May 2021).</p> </li> <li> <p>AMED Ovid (searched from 11 July 2018 to 5 May 2021).</p> </li> </ul> </p> <p>The Information Specialist modelled search strategies for other databases on the search strategy designed for CENTRAL. Where appropriate, they were combined with adaptations of the highly sensitive search strategy designed by the Cochrane Collaboration for identifying randomised controlled trials and controlled clinical trials (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Chapter 6, <a href="./references#CD010837-bbs2-0025" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Lefebvre 2011</a>). Search strategies for major databases are provided in <a href="./appendices#CD010837-sec-0068">Appendix 1</a>. </p> <p>The Information Specialist searched the following trials registries on 5 May 2021:</p> <p> <ul id="CD010837-list-0005"> <li> <p>The World Health Organization International Clinical Trials Registry Platform (<a href="http://who.int/trialsearch" target="_blank">who.int/trialsearch</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>). </p> </li> </ul> </p> </section> <section id="CD010837-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of relevant articles retrieved by the electronic searches for additional citations. </p> </section> </section> <section id="CD010837-sec-0026"> <h3 class="title" id="CD010837-sec-0026">Data collection and analysis</h3> <section id="CD010837-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (LR, CB) independently used the selection criteria to identify trials for inclusion. We resolved any disagreements by discussion. </p> </section> <section id="CD010837-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (LR, SEY) independently extracted the data and recorded information about the trial design, VTE definition and investigations to confirm diagnosis, baseline characteristics of participants and tests for cancer. All‐cause mortality, cancer‐related mortality and VTE‐related mortality data were recorded as the primary outcome measures. Information on VTE‐related morbidity (e.g. frequency of recurrent VTE), complications of anticoagulation (e.g. warfarin‐ versus LMWH‐associated bleeding), adverse effects of cancer tests (e.g. radiation exposure, bleeding), characteristics of diagnosed cancer (e.g. primary tumour, stage, localised (curable) versus advanced (palliative)), time to cancer diagnosis, frequency of an underlying cancer diagnosis and participant satisfaction was collected in accordance with the secondary outcome measures. Where more than one publication of one study existed, reports were grouped together and the most recent or most complete data set were used. We contacted authors of included studies for further information if clarification was required. We resolved any disagreements in data extraction and management by discussion. </p> </section> <section id="CD010837-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (LR, SEY) independently used the Cochrane tool to assess the risk of bias for each of the included studies (<a href="./references#CD010837-bbs2-0019" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). The tool provides a protocol for judgements on sequence generation, allocation methods, blinding, incomplete outcome data, selective outcome reporting and any other relevant biases. We judged each of these domains at high, low or unclear risk of bias according to <a href="./references#CD010837-bbs2-0019" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a> and provided support for each judgement. The conclusions are presented in a 'Risk of bias' table. Any disagreements were resolved by discussion. </p> </section> <section id="CD010837-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We planned to base the analysis on intention‐to‐treat data from the individual clinical trials. The majority of outcomes were binary measures (mortality, morbidity, complications, adverse effects, characteristics of diagnosed cancer, frequency of an underlying cancer diagnosis). For these outcomes, we computed odds ratios (ORs) using a random‐effects model and calculated the 95% CI of the effect sizes. For time to cancer diagnosis, we aimed to compute hazard ratios (HR), while for participant satisfaction, we planned to report results descriptively (<a href="./references#CD010837-bbs2-0017" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Deeks 2011</a>). </p> </section> <section id="CD010837-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis within each trial was the individual participant.</p> </section> <section id="CD010837-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We sought information about dropouts, withdrawals and other missing data and, if not reported, we contacted the study authors. </p> </section> <section id="CD010837-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between the pooled studies by visual examination of the forest plot to check for overlapping CIs, and used the Chi<sup>2</sup> test for homogeneity with a 10% level of significance. We used the I<sup>2</sup> statistic to measure the degree of inconsistency between the studies. An I<sup>2</sup> result of over 50% may represent moderate to substantial heterogeneity (<a href="./references#CD010837-bbs2-0017" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Deeks 2011</a>). </p> </section> <section id="CD010837-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess reporting biases such as publication bias using funnel plots when there were more than 10 studies in the meta‐analyses (<a href="./references#CD010837-bbs2-0041" title="SterneJA , EggerM , MoherD . Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Sterne 2011</a>). However, as there were only four studies in the review it was not possible to test for funnel plot asymmetry. </p> </section> <section id="CD010837-sec-0035"> <h4 class="title">Data synthesis</h4> <p>The review authors independently extracted the data. One review author (LR) entered the data into Review Manager 5 (<a href="./references#CD010837-bbs2-0034" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). A second review author (SEY) cross‐checked data entry and resolved any discrepancies by consulting the source publication. </p> <p>We used a random‐effects model for meta‐analysis of the data. We planned to stratify analyses according to the individual cancer test being assessed and the combination of tests as used in the SOMIT trial (<a href="./references#CD010837-bbs2-0032" title="PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al, SOMIT Investigators Group. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2(6):884-9.">Piccioli 2004a</a>). </p> </section> <section id="CD010837-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where possible, we planned to analyse clinically relevant subgroups based on the following:</p> <p> <ul id="CD010837-list-0006"> <li> <p>DVT or PE at time of randomisation;</p> </li> <li> <p>cancer site;</p> </li> <li> <p>treatment post‐investigation with vitamin K antagonist or LMWH;</p> </li> <li> <p>duration of anticoagulation (e.g. three or six months);</p> </li> <li> <p>age and gender of participants (comparing those in age and gender groups for national screening programmes to those not in these age and gender groups); </p> </li> <li> <p>time of randomisation after VTE diagnosis (within three months compared with after three months). </p> </li> </ul> </p> <p>However, due to lack of data in the studies, it was not possible to perform subgroup analysis. </p> </section> <section id="CD010837-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct a sensitivity analysis by excluding studies at high risk of bias to measure the effect on the results. We were not able to carry out sensitivity analysis due to the limited number of studies in each comparison. </p> </section> <section id="CD010837-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the main findings of the review results concerning the certainty of evidence, the magnitude of effect of the interventions examined and the sum of available data for all outcomes of this review (<a href="#CD010837-sec-0020">Types of outcome measures</a>) in a Summary of findings table, according to the GRADE principles as described by <a href="./references#CD010837-bbs2-0019" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a> and <a href="./references#CD010837-bbs2-0008" title="AtkinsD , BestD , BrissPA , EcclesM , Falck-YtterY , FlottorpS , et al, GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490-4.">Atkins 2004</a>. We calculated assumed control intervention risks from the mean number of events in the control groups of the selected studies for each outcome. We used the GRADEprofiler (<a href="https://www.guidelinedevelopment.org" target="_blank">GRADEpro</a>) software to assist in the preparation of the Summary of findings table. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010837-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010837-sec-0039"></div> <section id="CD010837-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD010837-sec-0041"> <h4 class="title">Results of the search</h4> <p>No new studies were identified for inclusion in this 2021 update. See <a href="#CD010837-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD010837-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010837-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We identified four additional reports relating to the previously included study <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a> (<a href="./references#CD010837-bbs2-0035" title="RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Supplement 1):1073.">Robin 2017a</a>; <a href="./references#CD010837-bbs2-0036" title="RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51.">Robin 2017b</a>; <a href="./references#CD010837-bbs2-0037" title="RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102.">Robin 2018</a>; <a href="./references#CD010837-bbs2-0038" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7.">Robin 2020</a>); and one additional report each for <a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a> (<a href="./references#CD010837-bbs2-0028" title="NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008).">NCT00773448</a>) and <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a> (<a href="./references#CD010837-bbs2-0027" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first posted 8 received 2006).">NCT00361647</a>). One new study was assessed as excluded (<a href="./references#CD010837-bbs2-0005" title="KraaijpoelN , vanEsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE Study. Thrombosis and Haemostasis2018;118(7):1270-8. [DOI: 10.1055/s-0038-1649523]">Kraaijpoel 2018</a>). We identified two new ongoing studies (<a href="./references#CD010837-bbs2-0006" title="EUCTR2018-003958-25-ES. Screening for cancer with a very effective imaging technique to early tumors in patients with unprovoked venous thromboembolic disease with a slight risk of developing cancer. Open randomized clinical trial. who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2018-003958-25-ES (first received 12 April 2019). NCT03937583. Screening for cancer in patients with thromboembolic disease. clinicaltrials.gov/ct2/show/NCT03937583 (first received 6 May 2019). ">EUCTR2018‐003958‐25‐ES</a>; <a href="./references#CD010837-bbs2-0007" title="EUCTR2020-002210-41-FR. Screening for occult malignancy using positron emission tomography/computed tomography (FDG PET/CT) in patients with unprovoked venous thromboembolism. clinicaltrialsregister.eu/ctr-search/trial/2020-002210-41/FR (first received 12 May 2020). NCT04304651. Screening for occult malignancy in patients with unprovoked venous thromboembolism. clinicaltrials.gov/ct2/show/NCT04304651 (first received 11 March 2020). ">EUCTR2020‐002210‐41‐FR</a>). </p> </section> <section id="CD010837-sec-0042"> <h4 class="title">Included studies</h4> <p>Four studies fulfilled the eligibility criteria for inclusion in this review (<a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a>; <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a>; <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a>; <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a>). </p> <p>See <a href="./references#CD010837-sec-0080" title="">Characteristics of included studies</a> table. </p> <p>The first study was a randomised multicentre study of 201 apparently cancer‐free people with acute unprovoked VTE (<a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a>). Extensive investigations for occult malignant disease were compared with testing at the physician's discretion. Ninety‐nine participants were randomised to the extensive screening group and 102 were randomised to the control group. Participants in the extensive investigations group were offered ultrasound and CT scans of the abdomen and pelvis, double contrast barium swallowing, colonoscopy or sigmoidoscopy followed by a barium enema, haemoccult test, sputum cytology and tumour markers including carcinoembryonic antigen (CEA), alpha‐fetoprotein (α‐FP) and CA125. Women also underwent mammography and Papanicolaou (Pap) smears while men had transabdominal ultrasound of the prostate and a total prostate‐specific antigen (PSA) test. All tests were completed within a four‐week period from the diagnosis of VTE. Participants in the control group were investigated at the physician's discretion. If the investigations suggested the presence of a malignant process, further investigations were performed according to current standards. Participants were followed up at 3, 12 and 24 months following the diagnosis of VTE. The primary outcome was cancer‐related morbidity, defined as death due to a malignant disease itself, or death due to complications of diagnostic or surgical procedures performed to diagnose or treat cancer. A secondary outcome of this study consisted of the cluster of cancer‐related mortality and documented residual malignancy or recurrent malignancy at 24 months. The authors also measured the frequency of an underlying cancer diagnosis including type and stage as well as mean time to cancer diagnosis. </p> <p>The second study was a randomised study in which 195 participants with a first episode of unprovoked VTE were randomised to extensive investigations (98 participants) or a discretionary diagnostic approach excluding CT scans (97 participants) (<a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a>). Extensive investigations comprised a mandatory CT scan of the thorax, abdomen and pelvis together with faecal haemoccult testing or any test at physician's discretion according to good clinical practice. Participants allocated to the discretionary diagnostic approach or personalised strategy underwent additional testing based on physicians' judgements and participants' preferences, including a 'no‐further testing' option. Participants were followed at 3, 6, 12 and 24 months to document the incidence of newly discovered cancer and cancer‐related mortality. The primary outcomes were cancer‐related mortality (defined as death due to malignancy, or death due to the complications of the diagnostic or surgical procedures performed to diagnose or treat cancer) and incidence of newly discovered cancer. The secondary outcomes were cancer stage, using the tumours‐nodes‐metastases classification, at which tumours were diagnosed in the two study groups and the incidence of cancer‐related mortality in the two randomisation groups, </p> <p>The third study was an open‐label randomised study in which 854 participants with a first episode of unprovoked VTE were randomised to limited occult‐cancer screening plus CT scanning of the abdomen and pelvis (423 participants) or limited occult‐cancer screening alone (431 participants) (<a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a>). The limited occult‐cancer screening comprised complete history and physical examination, measurement of complete blood counts and serum electrolyte and creatinine levels, liver‐function testing and chest radiography. Sex‐specific screening was conducted if it had not been performed in the previous year. A breast examination, mammography, or both were performed in women over 50 years of age and Pap testing and a pelvic examination were performed in women 18 to 70 years of age who had ever been sexually active. A prostate examination, PSA test, or both were performed in men over 40 years of age. The additional CT investigations comprised a virtual colonoscopy and gastroscopy, biphasic enhanced CT of the liver, parenchymal pancreatography and uniphasic enhanced CT of the distended bladder. Participants were followed up for one year to document the incidence of newly diagnosed cancer, type of cancer diagnosed, one‐year cancer‐related mortality, one‐year overall mortality, time to cancer diagnosis and incidence of recurrent VTE. </p> <p>The fourth study was an open‐label randomised study in which 394 participants with a first episode of unprovoked VTE were randomised to a limited screening strategy (197 participants) or a screening strategy consisting of the limited strategy plus an 18‐fluorodeoxyglucose (<sup>18</sup>F‐FDG) PET/CT scan of the chest, abdomen and pelvis (197 participants) (<a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a>). The limited screening comprised medical history taking, physical examination, routine laboratory tests (including complete blood count, erythrocyte sedimentation rate or C‐reactive protein, aminotransferases, alkaline phosphatase and calcium), chest radiograph, and recommended age‐specific and sex‐specific cancer screening tests (i.e. PSA in men older than 50 years, mammography in women older than 50 years and Pap smear in all women). Participants were followed up for two years to determine the proportion of people with a cancer diagnosis in each group after the initial screening assessment. </p> </section> <section id="CD010837-sec-0043"> <h4 class="title">Excluded studies</h4> <p>We identified one new excluded study (<a href="./references#CD010837-bbs2-0005" title="KraaijpoelN , vanEsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE Study. Thrombosis and Haemostasis2018;118(7):1270-8. [DOI: 10.1055/s-0038-1649523]">Kraaijpoel 2018</a>). See <a href="./references#CD010837-sec-0081" title="">Characteristics of excluded studies</a>. </p> <p>Studies that were not randomised controlled trials were deemed not relevant and therefore not listed as an excluded study. </p> </section> <section id="CD010837-sec-0044"> <h4 class="title">Ongoing studies</h4> <p>We identified two new ongoing studies (<a href="./references#CD010837-bbs2-0006" title="EUCTR2018-003958-25-ES. Screening for cancer with a very effective imaging technique to early tumors in patients with unprovoked venous thromboembolic disease with a slight risk of developing cancer. Open randomized clinical trial. who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2018-003958-25-ES (first received 12 April 2019). NCT03937583. Screening for cancer in patients with thromboembolic disease. clinicaltrials.gov/ct2/show/NCT03937583 (first received 6 May 2019). ">EUCTR2018‐003958‐25‐ES</a>; <a href="./references#CD010837-bbs2-0007" title="EUCTR2020-002210-41-FR. Screening for occult malignancy using positron emission tomography/computed tomography (FDG PET/CT) in patients with unprovoked venous thromboembolism. clinicaltrialsregister.eu/ctr-search/trial/2020-002210-41/FR (first received 12 May 2020). NCT04304651. Screening for occult malignancy in patients with unprovoked venous thromboembolism. clinicaltrials.gov/ct2/show/NCT04304651 (first received 11 March 2020). ">EUCTR2020‐002210‐41‐FR</a>). See <a href="./references#CD010837-sec-0082" title="">Characteristics of ongoing studies</a>. </p> </section> </section> <section id="CD010837-sec-0045"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD010837-fig-0002">Figure 2</a> and <a href="#CD010837-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010837-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010837-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010837-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010837-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010837-sec-0046"> <h4 class="title">Allocation</h4> <p>All four studies were randomised. <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a> used envelopes. <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a> used a Zelen approach (participants are randomised to either the treatment or control group before giving informed consent), <a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a> used random number tables and <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a> used a computer random number generator. Therefore, these four studies were judged at low risk of selection bias. In terms of concealing the allocation of treatment, <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a> performed randomisation centrally and <a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a> and <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a> used a central web‐based randomisation system and, therefore, these three were judged at low risk of selection bias. The <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a> study used serially numbered, opaque, sealed envelopes to conceal allocation and was, therefore, judged at low risk of selection bias too. </p> </section> <section id="CD010837-sec-0047"> <h4 class="title">Blinding</h4> <p>As the study groups in all four trials were randomised to extensive screening or no further testing, it was impossible to blind participants and study personnel. However, we believe it was unlikely that the lack of blinding would have affected the outcome and, therefore, all studies were judged at low risk of performance bias. </p> <p>In <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a>, the physician at the follow‐up examination was unaware of the allocation of participants and, therefore, detection bias for outcome assessors was low. Similarly, for <a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a> a blinded adjudication committee reviewed all suspected outcome events and, therefore, the risk of detection bias was low. <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a> did not blind outcome assessors to treatment allocation and was, therefore, judged at high risk of detection bias. In <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a>, investigators performing the follow‐up visits were blinded to the participants' randomisation group and the study was, therefore, judged at low risk of detection bias. </p> </section> <section id="CD010837-sec-0048"> <h4 class="title">Incomplete outcome data</h4> <p>The treatment groups in all four studies were well‐balanced with respect to baseline characteristics, completion of the study protocol and discontinuation of treatment. Furthermore, all missing data were accounted for and reported. Therefore, all four studies were judged at low risk of attrition bias (<a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a>; <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a>; <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a>; <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a>). </p> </section> <section id="CD010837-sec-0049"> <h4 class="title">Selective reporting</h4> <p>All four studies clearly prespecified all primary and secondary outcomes and data on all outcomes were reported (low risk of reporting bias) (<a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a>; <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a>; <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a>; <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a>). </p> </section> <section id="CD010837-sec-0050"> <h4 class="title">Other potential sources of bias</h4> <p>Two studies were deemed at low risk (<a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a>; <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a>), and two studies were deemed to be at high risk of other bias (<a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a>; <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a>). The study by <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a> was terminated early after the inclusion of only 201 participants after five years for several reasons. First, only five of the more than 40 potential participating centres could contribute participants to the study. Second, some medical ethics committees rejected the protocol because of the absence of screening for occult cancer in the control group, other centres could not start because the proposed extensive screening was judged to be unethical. Finally, the identification of cancer at an apparent early stage in the extensive screening group led to an increasing tendency among physicians in the participating hospitals to initiate screening for cancer in the control participants. The study by <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a> was judged at high risk of bias as results of an interim analysis, scheduled after the inclusion of approximately half of the planned sample size, showed no appreciable advantage of the CT‐based strategy over the control strategy for detection of occult cancers. In addition, there was a low recruitment rate, so the study promoters decided to terminate the study early. </p> </section> </section> <section id="CD010837-sec-0051"> <h3 class="title" id="CD010837-sec-0051">Effects of interventions</h3> <p>See: <a href="./full#CD010837-tbl-0001"><b>Summary of findings 1</b> Extensive tests versus tests at the physician's discretion</a>; <a href="./full#CD010837-tbl-0002"><b>Summary of findings 2</b> Standard testing plus PET/CT scanning versus standard testing alone</a> </p> <section id="CD010837-sec-0052"> <h4 class="title">Extensive tests versus tests at the physician's discretion</h4> <p>Two studies assessed the effect of testing for cancer versus clinically indicated tests only (<a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a>; <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a>). </p> <p>Both studies measured the primary outcome cancer‐related mortality. In <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a>, 2/99 participants in the extensive testing group died of cancer compared to 4/102 in the group who underwent tests at the physician's discretion (OR 0.51, 95% CI 0.09 to 2.82). In <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a>, 2/98 participants who underwent extensive testing and 4/97 participants who underwent tests at the physician's discretion died of cancer (OR 0.48, 95% CI 0.09 to 2.71). Meta‐analysis showed an OR of 0.49 (95% CI 0.15 to 1.67; low‐certainty evidence) in favour of extensive testing, which did not reach statistical significance (P = 0.26) (<a href="./references#CD010837-fig-0004" title="">Analysis 1.1</a>). </p> <p>However, neither <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a> nor <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a> measured the review's other primary outcomes of all‐cause mortality and VTE‐related mortality, or the secondary outcomes VTE‐related morbidity, complications of anticoagulation, adverse effects of cancer tests, participant satisfaction and quality of life. </p> <p><a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a> looked at the location of the malignancy and found no clear difference in the incidence of any particular cancer between participants who underwent extensive tests and participants who were tested at the physician's discretion (lung: OR 2.08, 95% CI 0.19 to 23.34; bladder: OR 2.08, 95% CI 0.19 to 23.34; stomach: OR 1.03, 95% CI 0.06 to 16.71; kidney: OR 3.12, 95% CI 0.13 to 77.55; adrenal gland: OR 3.12, 95% CI 0.13 to 77.55; liver: OR 3.12, 95% CI 0.13 to 77.55; uterus: OR 3.12, 95% CI 0.13 to 77.55; breast: OR 1.03, 95% CI 0.06 to 16.71; ovary: OR 3.12, 95% CI 0.13 to 77.55; colon: OR 0.51, 95% CI 0.05 to 5.72; prostate: OR 0.51, 95% CI 0.05 to 5.72; pancreas: OR 0.20, 95% CI 0.01 to 4.26) (<a href="./references#CD010837-fig-0005" title="">Analysis 1.2</a>). </p> <p><a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a> compared the characteristics of the diagnosed cancer by assessing the proportion of early‐stage malignancies, defined as T1 or T2 without locoregional or distant metastases (N0 M0). Overall, malignancies were less advanced in participants who had undergone extensive testing. In total, 9/13 participants diagnosed with cancer in the tested group had a T1‐ or T2‐stage malignancy without locoregional or distant metastases compared to 2/10 participants diagnosed with cancer in the control group (OR 5.00, 95% CI 1.05 to 23.76; P = 0.04; low‐certainty evidence). There was no difference in detection of advanced stages between groups: one participant in the tested group had stage T3 compared with four participants in the control group (OR 0.25, 95% CI 0.03 to 2.28; P = 0.22; low‐certainty evidence) (<a href="./references#CD010837-fig-0006" title="">Analysis 1.3</a>). </p> <p>One study measured time to cancer diagnosis (measured from the time of diagnosis of VTE) (<a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a>), reported as a mean of one month in tested participants compared to 11.6 months in participants who were tested at the physician's discretion (P &lt; 0.001). Standard deviations for the means were not given. We attempted to contact the author for these data but received no response. </p> <p>Both studies measured the frequency of an underlying cancer diagnosis. <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a> detected underlying cancer in 13/99 participants who underwent extensive testing, whereas it became symptomatic in 10/102 control participants (OR 1.39, 95% CI 0.58 to 3.34). <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a> detected cancer in 2/98 participants who had further tests and it became apparent in 2/97 participants who were tested at the physician's discretion (OR 0.99, 95% CI 0.14 to 7.17). The combined incidence of an underlying cancer diagnosis was 15/197 in the tested group and 12/199 in the control group (OR 1.32, 95% CI 0.59 to 2.93; low‐certainty evidence) (<a href="./references#CD010837-fig-0007" title="">Analysis 1.4</a>). Therefore, after 24 months of follow‐up, the incidence of cancer was no different in the tested and control groups. </p> </section> <section id="CD010837-sec-0053"> <h4 class="title">Standard testing plus PET/CT scanning versus standard testing alone</h4> <p>Two studies assessed the effect of standard testing plus PET/CT scanning versus standard testing alone (<a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a>; <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a>). </p> <p>Both studies measured the primary outcome all‐cause mortality. In the standard testing plus CT scanning group, 11/620 participants died during follow‐up compared to 9/628 participants who received standard testing alone (OR 1.22, 95% CI 0.49 to 3.04; moderate‐certainty evidence) (<a href="./references#CD010837-fig-0008" title="">Analysis 2.1</a>). </p> <p><a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a> and <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a> also measured cancer‐related mortality and reported an incidence of 6/620 participants with standard testing plus CT scanning compared to 11/628 participants who received standard testing alone (OR 0.55, 95% CI 0.20 to 1.52; moderate‐certainty evidence) (<a href="./references#CD010837-fig-0009" title="">Analysis 2.2</a>). </p> <p>The study by <a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a> measured VTE‐related morbidity. The incidence of recurrent VTE was 14/423 participants who underwent standard testing plus CT scanning compared to 14/431 participants who had standard testing alone (OR 1.02, 95% CI 0.48 to 2.17; moderate‐certainty evidence) (<a href="./references#CD010837-fig-0010" title="">Analysis 2.3</a>). </p> <p><a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a> and <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a> also looked at the location of the malignancy and found no clear difference in the incidence of any particular cancer between the two groups (acute leukaemia: OR 1.62, 95% CI 0.20 to 13.22; gynaecological: OR 2.39, 95% CI 0.43 to 13.36; melanoma: OR 1.02, 95% CI 0.06 to 16.34; colorectal: OR 0.43, 95% CI 0.08 to 2.40; prostate: OR 2.52, 95% CI 0.48 to 13.12; pancreatic: OR 4.81, 95% CI 0.55 to 42.48; cholangiocarcinoma: OR 0.51, 95% CI 0.05 to 5.63; lymphoma: OR 0.74, 95% CI 0.09 to 5.83; breast: OR 0.20, 95% CI 0.01 to 4.24; urological: OR 0.62, 95% CI 0.03 to 12.32; liver: OR 0.33, 95% CI 0.01 to 8.19; head and neck: OR 3.02, 95% CI 0.12 to 74.47; lung: OR 3.02, 95% CI 0.12 to 74.47; unknown primary origin: OR 0.34, 95% CI 0.01 to 8.34) (<a href="./references#CD010837-fig-0011" title="">Analysis 2.4</a>). </p> <p><a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a> also measured the stage of cancer. Early‐stage cancer was detected in 7/197 participants who underwent standard testing plus CT scanning compared to 4/197 participants who underwent standard testing alone (OR 1.78, 95% CI 0.51 to 6.17; low‐certainty evidence), while advanced‐stage cancer was detected in two participants in each group (OR 1.00, 95% CI 0.14 to 7.17; low‐certainty evidence) (<a href="./references#CD010837-fig-0012" title="">Analysis 2.5</a>). </p> <p>Time to cancer diagnosis was 4.0 months in the standard testing plus PET/CT group and 4.2 months in the standard testing group in one study (P = 0.88) (<a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a>). However, standard deviations for these means were not given. We attempted to contact the author for these data but received no response. <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a> did not measure time to cancer diagnosis. </p> <p><a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a> and <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a> measured the frequency of underlying cancer diagnosis. Underlying cancer was detected in 30/620 participants who underwent standard testing plus CT scanning compared to 18/628 participants who underwent standard testing alone (OR 1.71, 95% CI 0.91 to 3.20; moderate‐certainty evidence) (<a href="./references#CD010837-fig-0013" title="">Analysis 2.6</a>). </p> <p>The studies by <a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a> and <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a> did not measure the other review outcomes of VTE‐related mortality, complications of anticoagulation, adverse effects of cancer tests, participant satisfaction or quality of life. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010837-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010837-sec-0054"></div> <section id="CD010837-sec-0055"> <h3 class="title" id="CD010837-sec-0055">Summary of main results</h3> <p>Four studies fulfilled the eligibility criteria for inclusion in this review (<a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a>; <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a>; <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a>; <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a>). In total, 1644 participants were studied. We found no studies that were potentially eligible but then excluded. </p> <section id="CD010837-sec-0056"> <h4 class="title">Extensive tests versus tests at the physician's discretion</h4> <p>Two studies compared the effectiveness of testing for cancer on cancer‐related mortality in people with a first unprovoked VTE (<a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a>; <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a>). <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a> performed an extensive list of tests while <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a> carried out fewer tests. Pooled analysis showed that testing for cancer was consistent with either a benefit or no benefit on cancer‐related mortality. Testing did not increase the frequency of an underlying cancer diagnosis. However, the time to cancer diagnosis was shorter in tested participants (mean: one month with extensive tests versus 11 months with tests at the physician's discretion). Furthermore, more people had a detection of early‐stage cancer with extensive tests compared to people who were tested at the physician's discretion (<a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a>). However, standard deviations for the mean time to diagnosis were not reported and, therefore, it was impossible to independently test the statistical significance of this result. Neither study measured all‐cause mortality, VTE‐related morbidity and mortality, adverse effects of anticoagulation, adverse effects of cancer tests, participant satisfaction or quality of life. </p> </section> <section id="CD010837-sec-0057"> <h4 class="title">Standard testing plus PET/CT scanning versus standard testing alone</h4> <p>Two studies compared limited screening plus PET/CT scanning of the abdomen and pelvis with limited screening alone in people with a first unprovoked VTE (<a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a>; <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a>). Standard testing plus PET/CT scanning was consistent with either a benefit or no benefit on all‐cause mortality, cancer‐related mortality and VTE‐related morbidity. Extensive testing did not increase the frequency of an underlying cancer diagnosis. Furthermore, there was no clear difference in the incidence of particular types of cancer or the stage of cancer between the extensive and standard testing groups. One study measured time to cancer diagnosis but standard deviations for the mean time to diagnosis were not reported and, therefore, it was impossible to independently test the statistical significance of this result (<a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a>). <a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a> and <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a> did not measure VTE‐related mortality, adverse effects of anticoagulation, adverse effects of cancer tests, participant satisfaction or quality of life. </p> <p>A follow‐up publication to <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a> assessed the cost‐effectiveness of screening plus PET/CT in comparison with limited screening from the publicly‐funded health care systems perspective (Ontario, Canada and France; <a href="./references#CD010837-bbs2-0037" title="RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102.">Robin 2018</a>). This post‐hoc analysis found that the addition of PET/CT scan to screening for occult cancer diagnosis is more expensive than standard screening (screening and follow‐up total cost per patient (SD): Ontario health system screening plus PET/CT CAD 1324.08 (236.89) versus standard screening CAD 211.75 (315.51); French health system screening plus PET/CT EUR 817.52 (111.43) versus standard screening EUR 96.89 (187.81)). Compared to standard screening, the incremental cost per quality‐adjusted life year (QALY) gained was CAD 3412.85 (95% CI 1463.89 to 13,935.88) from the Ontario health system perspective, and EUR 2162.83 (95% CI 958.78 to 10,544.42) from the French health system perspective (<a href="./references#CD010837-bbs2-0037" title="RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102.">Robin 2018</a>). </p> </section> </section> <section id="CD010837-sec-0058"> <h3 class="title" id="CD010837-sec-0058">Overall completeness and applicability of evidence</h3> <p>At present, there is limited evidence concerning whether testing for undiagnosed cancer in people with a first episode of unprovoked VTE (DVT or PE) is effective in reducing cancer‐ and VTE‐related mortality and morbidity and which tests for cancer are most useful. Only four studies met the inclusion criteria for this review (<a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a>; <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a>; <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a>; <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a>). While the losses to follow‐up were equally balanced within each study, the number of participants in each study was relatively small and pooled analysis is based on 1644 participants. Furthermore, the four studies primarily looked at cancer‐related mortality and incidence of cancer diagnosis as their main outcomes. Other outcomes of interest for this review, such as VTE‐related mortality, adverse effects of anticoagulation, adverse effects of cancer tests and quality of life, were not studied and, therefore, remain unknown. </p> </section> <section id="CD010837-sec-0059"> <h3 class="title" id="CD010837-sec-0059">Quality of the evidence</h3> <p>One study included in the review was judged at low risk of bias (<a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a>). <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a> was judged at high risk of bias as the study was terminated early for several reasons. First, only five of the more than 40 potential participating centres could contribute participants to the study. Second, some medical ethics committees rejected the protocol because of the absence of screening for occult cancer in the control group, other centres could not start because the proposed extensive screening was judged to be unethical. Finally, the identification of cancer at an apparent early stage in the extensive screening group led to an increasing tendency among physicians in the participating hospitals to initiate screening for cancer in the control participants. <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a> was judged at low risk for all domains except other bias, where the risk was deemed to be high as, based on an interim analysis, the study was terminated early because of the low recruitment rate and of the failure to show an appreciable advantage of the CT‐based strategy over the control strategy for detection of cancers. <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a> was judged at low risk for all domains except detection bias, where the risk was deemed high due to lack of blinding of outcome assessors. </p> <p>For the comparison extensive tests for cancer versus tests at the physician's discretion, the certainty of the evidence for cancer‐related mortality and frequency of an underlying cancer diagnosis was downgraded to low as there was a high risk of bias in both studies due to them both being terminated early. However, the outcome was direct and effect estimates were consistent and precise, as reflected in the narrow CIs around the ORs (<a href="./full#CD010837-tbl-0001">summary of findings Table 1</a>). The certainty of evidence for type of cancer are presented in a Summary of findings table (<a href="./appendices#CD010837-sec-0069">Appendix 2</a>). For type of cancer, the evidence was downgraded to low certainty as there was imprecision due to low number of events combined with the study being terminated early. </p> <p>For the comparison standard testing plus PET/CT scanning versus standard testing alone, the certainty of the evidence was graded as moderate for all‐cause mortality and cancer‐related mortality due to the high risk of detection bias in <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a>. For VTE‐related morbidity, the certainty of the evidence was downgraded to moderate as only one study measured this outcome. For stage of cancer, the evidence was downgraded to low as there was imprecision due to low number of events and there was a high risk of detection bias (<a href="./full#CD010837-tbl-0002">summary of findings Table 2</a>). The certainty of evidence for type of cancer are presented in a summary of findings table in <a href="./appendices#CD010837-sec-0070">Appendix 3</a>. For type of cancer, the evidence was judged to be moderate if there was imprecision due to low number of events or where the study was at high risk of detection bias. Where both imprecision and detection bias occurred together, the certainty of the evidence was downgraded to low. </p> </section> <section id="CD010837-sec-0060"> <h3 class="title" id="CD010837-sec-0060">Potential biases in the review process</h3> <p>None of the authors of this review were involved in any of the included or excluded studies. Furthermore, none have any commercial or other conflicts of interest. The search was as comprehensive as possible, and all studies were independently assessed for inclusion by two review authors. We are confident that we have included all relevant studies and we have attempted to reduce bias in the review process by performing data extraction and assessing study quality independently. However, the possibility remains that we may have missed studies that have not been published. </p> <p>We judged blinding of investigators and participants to be at low risk of bias. It would have been impossible to blind participants and staff to tests such as scans. Therefore, there is a risk of cross‐over bias in participants in the control group with them having further tests. However, the effect of this would be to minimise the apparent benefit from testing that was observed, and, therefore, this does not detract from the conclusions of the study or review. </p> <p>In this review, we presented the studies by <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a> and <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a> together as both studies compared extensive tests for cancer versus "tests at the physicians discretion". The studies by <a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a> and <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a> were reported in a separate analysis as both studies compared limited screening plus PET/CT scanning versus limited screening alone. Combining all four studies in a meta‐analysis would have been problematic due to the different definitions of the comparator groups. However, the control group of the <a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a> and <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a> studies included some of the tests in the test group of the studies by <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a> and <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a>, which may account for why there was no clear difference observed, along with participation of all people in breast and colorectal cancer screening programmes. This may also be the reason for the very low incidence of cancer in the studies by <a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a> and <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a> compared to the studies by <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a> and <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a>. </p> </section> <section id="CD010837-sec-0061"> <h3 class="title" id="CD010837-sec-0061">Agreements and disagreements with other studies or reviews</h3> <p>To date, three other systematic reviews have assessed the effectiveness of testing for cancer on cancer‐related mortality in people with an unprovoked VTE. <a href="./references#CD010837-bbs2-0043" title="vanEsN , Le GalG , OttenHM , RobinP , PiccioliA , LecumberriR , et al. Screening for occult cancer in patients with unprovoked venous thromboembolism. Annals of Internal Medicine2017;167(6):410-7.">van Es 2017</a> conducted a systematic review and meta‐analysis of individual patient data from ten prospective studies. Only two of these were randomised controlled trials, both of which were also included in our meta‐analysis (<a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a>; <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a>). The primary outcome was prevalence of occult cancer in patients with an unprovoked VTE. The prevalence of cancer 12 months after VTE diagnosis was 5.2% (95% CI 4.1% to 6.5%). The prevalence of cancer was higher in patients who had extensive testing than in those who had more limited testing initially (OR 2.0, 95% CI 1.2 to 3.4) but not at 12 months (OR 1.4 95% CI 0.89 to 2.1). Furthermore, the prevalence of cancer increased with age, and was seven‐fold higher in patients aged 50 years or older, than in younger patients (OR 7.1, 95% CI 3.1 to 16.0). Systematic reviews by <a href="./references#CD010837-bbs2-0022" title="KleinA , ShepshelovichD , SpectreG , GoldvaserH , RaananiP , Gafter-GviliA . Screening for occult cancer in idiopathic venous thromboembolism - systemic review and meta-analysis. European Journal of Internal Medicine2017;42:74-80.">Klein 2017</a> and <a href="./references#CD010837-bbs2-0046" title="ZhouM , ZhangL , DingY , WangY , YanD , LinC , et al. Extensive screening for occult malignancy in unprovoked venous thromboembolism: a meta-analysis. Thrombosis Research2017;157:147-53.">Zhou 2017</a> evaluated the efficacy of an extensive testing strategy for occult malignant diseases in patients with unprovoked VTE. Both reviews included five studies; the same four studies included in our review (<a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a>; <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a>; <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a>; <a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a>) and a fifth study which was a prospective cohort study (<a href="./references#CD010837-bbs2-0042" title="vanDoormaalFF , TerpstraW , van derGriendR , PrinsMH , NijzielMR , vande ReeMA , et al. Is extensive screening for cancer in idiopathic venous thromboembolism warranted?Journal of Thrombosis and Haemostasis2011;9:79-84.">van Doormaal 2011</a>). This did not meet the inclusion criteria for our review as we considered randomised controlled trials only. Neither review demonstrated a significant difference between extensive and limited testing for all‐cause mortality (with risk ratios (RR) of 0.86, 95% CI 0.58 to 1.27 and RR 0.86, 95% CI, 0.58 to1.27 for <a href="./references#CD010837-bbs2-0022" title="KleinA , ShepshelovichD , SpectreG , GoldvaserH , RaananiP , Gafter-GviliA . Screening for occult cancer in idiopathic venous thromboembolism - systemic review and meta-analysis. European Journal of Internal Medicine2017;42:74-80.">Klein 2017</a> and <a href="./references#CD010837-bbs2-0046" title="ZhouM , ZhangL , DingY , WangY , YanD , LinC , et al. Extensive screening for occult malignancy in unprovoked venous thromboembolism: a meta-analysis. Thrombosis Research2017;157:147-53.">Zhou 2017</a>, respectively), nor cancer‐related mortality (RR 0.93, 95% CI 0.54 to 1.58 and RR 0.86, 95% CI, 0.46 to 1.62 for <a href="./references#CD010837-bbs2-0022" title="KleinA , ShepshelovichD , SpectreG , GoldvaserH , RaananiP , Gafter-GviliA . Screening for occult cancer in idiopathic venous thromboembolism - systemic review and meta-analysis. European Journal of Internal Medicine2017;42:74-80.">Klein 2017</a> and <a href="./references#CD010837-bbs2-0046" title="ZhouM , ZhangL , DingY , WangY , YanD , LinC , et al. Extensive screening for occult malignancy in unprovoked venous thromboembolism: a meta-analysis. Thrombosis Research2017;157:147-53.">Zhou 2017</a>, respectively). <a href="./references#CD010837-bbs2-0046" title="ZhouM , ZhangL , DingY , WangY , YanD , LinC , et al. Extensive screening for occult malignancy in unprovoked venous thromboembolism: a meta-analysis. Thrombosis Research2017;157:147-53.">Zhou 2017</a> found no significant difference between the extensive and limited testing groups with regard to risk of missed cancer diagnosis (RR 0.51, 95% CI 0.20 to 1.28). However, <a href="./references#CD010837-bbs2-0022" title="KleinA , ShepshelovichD , SpectreG , GoldvaserH , RaananiP , Gafter-GviliA . Screening for occult cancer in idiopathic venous thromboembolism - systemic review and meta-analysis. European Journal of Internal Medicine2017;42:74-80.">Klein 2017</a> determined that extensive testing yielded more diagnoses of cancer (RR 2.17, 95% CI 1.42 to 3.32). A more recent narrative review reported similar findings to this Cochrane Review as well as highlighting ongoing studies involving high‐risk patients (<a href="./references#CD010837-bbs2-0016" title="D'AstousJ , CarrierM . Screening for occult cancer in patients with venous thromboembolism. Journal of Clinical Medicine2020;9(8):2389. [DOI: 10.3390/jcm9082389#7305]">D'Astous 2020</a>). These ongoing studies were identified in our searches and will be included in future updates of this Cochrane Review. <a href="./references#CD010837-bbs2-0016" title="D'AstousJ , CarrierM . Screening for occult cancer in patients with venous thromboembolism. Journal of Clinical Medicine2020;9(8):2389. [DOI: 10.3390/jcm9082389#7305]">D'Astous 2020</a> also mentioned that other means of occult cancer detection, such as biomarkers, are being investigated. Biomarkers may allow more targeted screening, and platelet RNA profiling is currently being evaluated in a prospective cohort study to detect occult cancer in patients with unprovoked VTE (<a href="./references#CD010837-bbs2-0029" title="NCT02739867. Tumor-educated platelets in venous thromboembolism. clinicaltrials.gov/ct2/show/NCT02739867 (first received 15 April 2016).">NCT02739867</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010837-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/urn:x-wiley:14651858:media:CD010837:CD010837-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010837-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_t/tCD010837-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/full#CD010837-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010837-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/urn:x-wiley:14651858:media:CD010837:CD010837-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010837-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_t/tCD010837-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/full#CD010837-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010837-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/urn:x-wiley:14651858:media:CD010837:CD010837-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010837-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_t/tCD010837-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/full#CD010837-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010837-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/urn:x-wiley:14651858:media:CD010837:CD010837-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Extensive tests versus tests at the physician's discretion, Outcome 1: Cancer‐related mortality" data-id="CD010837-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_t/tCD010837-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Extensive tests versus tests at the physician's discretion, Outcome 1: Cancer‐related mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/references#CD010837-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010837-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/urn:x-wiley:14651858:media:CD010837:CD010837-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Extensive tests versus tests at the physician's discretion, Outcome 2: Characteristics of diagnosed cancer: type of cancer" data-id="CD010837-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_t/tCD010837-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Extensive tests versus tests at the physician's discretion, Outcome 2: Characteristics of diagnosed cancer: type of cancer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/references#CD010837-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010837-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/urn:x-wiley:14651858:media:CD010837:CD010837-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Extensive tests versus tests at the physician's discretion, Outcome 3: Characteristics of diagnosed cancer: stage of cancer" data-id="CD010837-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_t/tCD010837-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Extensive tests versus tests at the physician's discretion, Outcome 3: Characteristics of diagnosed cancer: stage of cancer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/references#CD010837-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010837-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/urn:x-wiley:14651858:media:CD010837:CD010837-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Extensive tests versus tests at the physician's discretion, Outcome 4: Frequency of underlying cancer diagnosis" data-id="CD010837-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_t/tCD010837-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Extensive tests versus tests at the physician's discretion, Outcome 4: Frequency of underlying cancer diagnosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/references#CD010837-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010837-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/urn:x-wiley:14651858:media:CD010837:CD010837-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard testing plus PET/CT scanning versus standard testing alone, Outcome 1: All‐cause mortality" data-id="CD010837-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_t/tCD010837-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Standard testing plus PET/CT scanning versus standard testing alone, Outcome 1: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/references#CD010837-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010837-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/urn:x-wiley:14651858:media:CD010837:CD010837-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard testing plus PET/CT scanning versus standard testing alone, Outcome 2: Cancer‐related mortality" data-id="CD010837-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_t/tCD010837-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Standard testing plus PET/CT scanning versus standard testing alone, Outcome 2: Cancer‐related mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/references#CD010837-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010837-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/urn:x-wiley:14651858:media:CD010837:CD010837-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard testing plus PET/CT scanning versus standard testing alone, Outcome 3: Venous thromboembolism‐related morbidity" data-id="CD010837-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_t/tCD010837-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Standard testing plus PET/CT scanning versus standard testing alone, Outcome 3: Venous thromboembolism‐related morbidity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/references#CD010837-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010837-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/urn:x-wiley:14651858:media:CD010837:CD010837-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard testing plus PET/CT scanning versus standard testing alone, Outcome 4: Characteristics of diagnosed cancer: type of cancer" data-id="CD010837-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_t/tCD010837-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Standard testing plus PET/CT scanning versus standard testing alone, Outcome 4: Characteristics of diagnosed cancer: type of cancer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/references#CD010837-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010837-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/urn:x-wiley:14651858:media:CD010837:CD010837-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard testing plus PET/CT scanning versus standard testing alone, Outcome 5: Characteristics of diagnosed cancer: stage of cancer" data-id="CD010837-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_t/tCD010837-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Standard testing plus PET/CT scanning versus standard testing alone, Outcome 5: Characteristics of diagnosed cancer: stage of cancer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/references#CD010837-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010837-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/urn:x-wiley:14651858:media:CD010837:CD010837-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard testing plus PET/CT scanning versus standard testing alone, Outcome 6: Frequency of an underlying cancer diagnosis" data-id="CD010837-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_t/tCD010837-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Standard testing plus PET/CT scanning versus standard testing alone, Outcome 6: Frequency of an underlying cancer diagnosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/references#CD010837-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/media/CDSR/CD010837/image_n/nCD010837-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010837-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Extensive tests versus tests at the physician's discretion</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Extensive tests versus tests at the physician's discretion</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with unprovoked VTE </p> <p><b>Setting:</b> hospital </p> <p><b>Intervention:</b> extensive tests </p> <p><b>Comparison:</b> tests at the physician's discretion </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with tests at physician's discretion</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with extensive tests</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cancer‐related mortality</b><sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.49<br/>(0.15 to 1.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>396<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>(6 to 65) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VTE‐related mortality</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>VTE‐related morbidity</b><sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stage of cancer ‐ early</b><sup>6</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 5.00<br/>(1.05 to 23.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>201</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000<br/>(21 to 322) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stage of cancer ‐ advanced</b><sup>8</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.25<br/>(0.03 to 2.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>201<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/>(1 to 85) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to cancer diagnosis</b><sup>9</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to cancer diagnosis (measured from time of diagnosis of VTE) measured in 1 study (<a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a>), and reported as a mean of 1 month with extensive tests compared to 11.6 months with tests at physician's discretion (P &lt; 0.001). Standard deviations for these means not given. Attempts to contact author for these data made but no response received. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency of underlying cancer diagnosis</b><sup>10</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 1000<br/>(36 to 158) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.32<br/>(0.59 to 2.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>396<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Death due to any cause.<br/><sup>2</sup> Defined as death due to malignant disease itself, or death due to complications of treatments or procedures to diagnose or treat cancer.<br/><sup>3</sup> Risk of bias was high in two included studies (<a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a>; <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a>). <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a> terminated early after inclusion of only 201 participants after 5 years for several reasons. First, only five of more than 40 potential participating centres could contribute participants to study. Second, some medical ethics committees rejected the protocol because of absence of screening for occult cancer in the control group, other centres could not start because the proposed extensive screening was judged unethical. Finally, identification of cancer at an apparent early stage in extensive screening group led to an increasing tendency among physicians in participating hospitals to initiate screening for cancer in control participants. <a href="./references#CD010837-bbs2-0003" title="NCT00361647. Screening for occult malignancy in idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00361647 (first received 8 August 2006). PiccioliA , BernardiE , Dalla ValleF , VisonàA , TropeanoPF , BovaC , et al. The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study. Thrombosis Research2012;129 Suppl 1:S155-94. PiccioliA , BernardiE , Dalla ValleF , VisonaA , TropeanoF , BovaC , et al. The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D'Acquapendente study. Journal of Thrombosis and Haemostasis2013;11 (Suppl 2):50-1. PiccioliA . The value of CT scanning for detection of occult cancer in patients with idiopathic VTE. In: Cancer, thrombosis and low-molecular-weight heparins (dare.uva.nl/record/1/465654 (accessed June 2016)). Amsterdam (the Netherlands): University of Amsterdam, 2015. PrandoniP , BernardiE , Dalla ValleF , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Blood Transfusion2016;14(Suppl 5):s745-6. PrandoniP , BernardiE , ValleFD , VisonaA , TropeanoPF , BovaC , et al. Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Seminars in Thrombosis and Hemostasis2016;42(8):884-90. ">Prandoni 2016</a> study terminated early due to low recruitment rate and failure to show an appreciable advantage of CT‐based strategy over control strategy for detection of cancer.<br/><sup>4</sup> Fatal pulmonary embolism (PE). PE diagnosed "on the basis of a lung scan indicating a high probability of its presence, as indicated by the presence of new or enlarged areas of segmental perfusion defects with ventilation‐perfusion mismatch; an abnormal perfusion scan with documentation of new or recurrent deep vein thrombosis (DVT); the presence of non‐enhancing filling defects in the central pulmonary vasculature on helical computed tomography; a finding of intraluminal filling defects on pulmonary angiography; or evidence of fresh PE at autopsy" (<a href="./references#CD010837-bbs2-0024" title="LeeAYY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53.">Lee 2003b</a>). Fatal PE including probable fatal PE and unexplained sudden death used if reported, as defined by individual studies.<br/><sup>5</sup> Frequency of recurrent VTE. Recurrent PE or DVT diagnosed if a previously compressible proximal venous segment or segments could no longer be compressed on ultrasonography or if there were constant intraluminal filling defects in two or more projections on venography. Unequivocal extension of the thrombus required for diagnosis of recurrence if results abnormal on previous testing (<a href="./references#CD010837-bbs2-0024" title="LeeAYY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53.">Lee 2003b</a>)<br/><sup>6</sup> Early‐stage malignancies, defined as T1 or T2 without locoregional or distant metastases (N0 M0).<br/><sup>7</sup> Certainty of evidence downgraded for imprecision due to low number of events. Evidence downgraded further as risk of bias high in <a href="./references#CD010837-bbs2-0002" title="OttenHM , PrinsMH . A number needed to screen and cost-effectiveness analysis of the SOMIT-data. Haemostasis2001;31 (Suppl 1):40-2. PiccioliA , LensingAW , PrinsMH , FalangaA , ScannapiecoGL , IeranM , et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Journal of Thrombosis and Haemostasis2004;2:884-9. ">Piccioli 2004b</a>. Study terminated early after inclusion of only 201 participants after five years for several reasons. First, only five of more than 40 potential participating centres could contribute participants to study. Second, some medical ethics committees rejected the protocol because of absence of screening for occult cancer in the control group, other centres could not start because the proposed extensive screening was judged unethical. Finally, identification of cancer at an apparent early stage in extensive screening group led to an increasing tendency among physicians in participating hospitals to initiate screening for cancer in control participants.<br/><sup>8</sup> Advanced‐stage malignancies, defined as T3 with locoregional or distant metastases (N1 or M1).<br/><sup>9</sup> Time to cancer diagnosis, as defined in included studies.<br/><sup>10</sup> Frequency of an underlying cancer diagnosis (i.e. number of times cancer diagnosed through screening following an unprovoked VTE as defined in included studies) at time of VTE presentation and overall over follow‐up period. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Extensive tests versus tests at the physician's discretion</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/full#CD010837-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010837-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Standard testing plus PET/CT scanning versus standard testing alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Standard testing plus PET/CT scanning versus standard testing alone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with unprovoked VTE </p> <p><b>Setting:</b> hospital </p> <p><b>Intervention:</b> standard testing + PET/CT scanning </p> <p><b>Comparison:</b> standard testing alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with standard testing alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with standard testing + PET/CT scanning</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.22<br/>(0.49 to 3.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1248<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000<br/>(7 to 42) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cancer‐related mortality</b><sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.55<br/>(0.20 to 1.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1248<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/>(4 to 26) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VTE‐related mortality</b><sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study measured this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>VTE‐related morbidity</b><sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.02<br/>(0.48 to 2.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>854<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000<br/>(16 to 68) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stage of cancer ‐ early</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.78<br/>(0.51 to 6.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>394<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2,6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/>(10 to 113) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stage of cancer ‐ advanced</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.00<br/>(0.14 to 7.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>394<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2,6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/>(1 to 69) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to cancer diagnosis</b><sup>7</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>854</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to cancer diagnosis measured in <a href="./references#CD010837-bbs2-0001" title="CarrierM , Lazo-LangnerA , ShivakumarS , TagalakisV , ZarychanskiR , SolymossS , et al. Screening for occult cancer in unprovoked venous thromboembolism. New England Journal of Medicine2015;373(8):697-704. CoyleK , CarrierM , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV , et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thrombosis Research2017;151:67-71. IhaddadeneR , CorsiDJ , Lazo-LangnerA , ShivakumarS , ZarychanskiR , TagalakisV . Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood2016;127(16):2035-7. NCT00773448. Screening for occult malignancy in patients with idiopathic venous thromboembolism. clinicaltrials.gov/show/NCT00773448 (first received 16 October 2008). ">Carrier 2015</a> as 4.2 months in standard testing group and 4.0 months in standard testing + PET/CT group (P = 0.88). However, standard deviations for these means not given. Attempts made to contact author for these data but no response received. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Frequency of an underlying cancer diagnosis</b><sup>8</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.71<br/>(0.91 to 3.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1248<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000<br/>(26 to 86) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>PET/CT:</b> positron emission tomography/computed tomography; <b>RCT:</b> randomised controlled trial; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Death due to any cause.<br/><sup>2</sup> Certainty of evidence downgraded as risk of detection bias high for one study as outcome assessors not blinded to treatment (<a href="./references#CD010837-bbs2-0004" title="RobinP , GrewalRK , Le RouxPY , Le GalG , SalaunPY . Interobserver agreement of 18F-fluorodeoxyglucose positron-emission tomography combined with low-dose computed tomography for occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research2020;188:25-7. RobinP , KumarS , SalaunPY , Le RouxPY , CouturaudF , PlanquetteB , et al. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research2018;171:97-102. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyP , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Thrombosis Research2017;155:6-9. RobinP , Le RouxPY , Le MoigneE , PlanquetteB , Prevot-BitotN , RoyPM , et al. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2017;1(Suppl 1):1073. RobinP , Le RouxPY , PlanquetteB , AccassatS , RoyPM , CouturaudF , et al. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology2016;17(2):193-9. RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism: results from the MVTEP study. Thrombosis Research2017;159:48-51. [DOI: 10.1016/j.thromres.2017.08.021]RobinP , Le RouxPY , TromeurC , PlanquetteB , Prevot-BitotN , LavigneC , et al. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research2017;159:48-51. ">Robin 2016</a>).<br/><sup>3</sup> Defined as death due to malignant disease itself, or death due to complications of treatments or procedures to diagnose or treat cancer.<br/><sup>4</sup> Fatal pulmonary embolism (PE). PE diagnosed "on the basis of a lung scan indicating a high probability of its presence, as indicated by the presence of new or enlarged areas of segmental perfusion defects with ventilation‐perfusion mismatch; an abnormal perfusion scan with documentation of new or recurrent deep vein thrombosis (DVT); the presence of non‐enhancing filling defects in the central pulmonary vasculature on helical computed tomography; a finding of intraluminal filling defects on pulmonary angiography; or evidence of fresh PE at autopsy" (<a href="./references#CD010837-bbs2-0024" title="LeeAYY , LevineMN , BakerRI , BowdenC , KakkarAK , PrinsM , et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine2003;349(2):146-53.">Lee 2003b</a>). Fatal PE including probable fatal PE and unexplained sudden death used if reported, as defined by individual studies.<br/><sup>5</sup> Frequency of recurrent VTE. Recurrent PE or DVT diagnosed if a previously compressible proximal venous segment or segments could no longer be compressed on ultrasonography or if there were constant intraluminal filling defects in two or more projections on venography.<br/><sup>6</sup> Certainty of evidence downgraded for imprecision due to low number of events.<br/><sup>7</sup> Time to cancer diagnosis, as defined in included studies.<br/><sup>8</sup> Frequency of an underlying cancer diagnosis (i.e. number of times cancer diagnosed through screening following an unprovoked VTE as defined in included studies) at time of VTE presentation and overall over follow‐up period. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Standard testing plus PET/CT scanning versus standard testing alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/full#CD010837-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010837-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Extensive tests versus tests at the physician's discretion</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Cancer‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.15, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Characteristics of diagnosed cancer: type of cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Lung</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [0.19, 23.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Bladder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [0.19, 23.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Stomach</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.06, 16.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 Kidney</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.13, 77.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.5 Adrenal gland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.13, 77.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.6 Liver</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.13, 77.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.7 Uterus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.13, 77.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.8 Breast</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.06, 16.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.9 Ovary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.13, 77.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.10 Colon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.05, 5.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.11 Prostate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.05, 5.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.12 Pancreas</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Characteristics of diagnosed cancer: stage of cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 T1 or T2 (N0 M0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [1.05, 23.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 T3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Frequency of underlying cancer diagnosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.59, 2.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Extensive tests versus tests at the physician's discretion</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/references#CD010837-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010837-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Standard testing plus PET/CT scanning versus standard testing alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.49, 3.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Cancer‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.20, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Venous thromboembolism‐related morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.48, 2.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Characteristics of diagnosed cancer: type of cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Acute leukaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.20, 13.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Gynaecological</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [0.43, 13.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.3 Skin: melanoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.06, 16.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.4 Colorectal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.08, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.5 Prostate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.52 [0.48, 13.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.6 Pancreatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.81 [0.55, 42.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.7 Cholangiocarcinoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.05, 5.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.8 Lymphoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.09, 5.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.9 Breast</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.10 Urological</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.03, 12.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.11 Liver</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.12 Head and neck</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.02 [0.12, 74.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.13 Lung</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.02 [0.12, 74.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.14 Unknown primary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Characteristics of diagnosed cancer: stage of cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Early</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.51, 6.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Advanced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.14, 7.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Frequency of an underlying cancer diagnosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.91, 3.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Standard testing plus PET/CT scanning versus standard testing alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010837.pub5/references#CD010837-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010837.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010837-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010837-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010837-note-0009">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD010837-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010837-note-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD010837-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010837\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010837\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010837\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010837\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010837\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010837\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010837\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010837\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010837\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010837\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010837\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010837\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010837\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010837\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010837\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010837\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010837\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010837\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010837.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010837.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010837.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010837.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010837.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725205861"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010837.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725205864"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010837.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e75909b2c1be5',t:'MTc0MDcyNTIwNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 